Abstract
The promise of pharmacogenomics includes managing patient-to-patient variability, developing better drugs faster and cheaper, and providing better medical care. However, whether there would be cost savings in clinical trials and the emergence of pharmacoeconomic modeling for diagnostic tests is still under consideration. In this talk, I would like to discuss these issues from clinical and discovery aspects of pharmacogenomics. Other ethical concerns including genomic data acquisition, data analysis, sensitivity and specificity, confidentiality and storage of patient sample, will be discussed as well. How to integrate the driven technologies with informatics will be one of the key issues to success.
